Effect of Nirsevimab as a Primary Preventive Strategy on the Incidence, Severity, and Viral Etiology of Bronchiolitis: A Four‐Year Observational Study
Pediatric Pulmonology · 2026
DOI: 10.1002/ppul.71451 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Pediatric Pulmonology, 2026. Verfasst von Santiago Presti und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Pulmonology and Cystic Fibrosis Unit, AOU Policlinico "G. Rodolico-San Marco", University of Catania, Catania, Italy. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Respiratory Syncytial Virus Infections, Antiviral Agents, Bronchiolitis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben.
Abstract (Originalsprache)
Background
Bronchiolitis is a prevalent viral respiratory illness in infants, often caused by respiratory syncytial virus (RSV). It is the leading cause of hospitalization in children under 1 year of age. The introduction of Nirsevimab, a long‐acting monoclonal antibody approved in 2022, aimed to reduce RSV‐related hospitalizations and severe cases. This study assesses the impact of Nirsevimab on bronchiolitis incidence, severity, and viral etiology in Sicily from 2021 to 2025.
Methods
This observational study included all pediatric patients hospitalized for bronchiolitis at the University of Catania's Pediatric Respiratory Unit between October 2021 and March 2025. Data were collected on viral etiology, hospital stay duration, clinical severity and respiratory support requirements across four epidemic seasons. Statistical analysis was used to compare outcomes across the different years, with a focus on the 2024–2025 season, which was the first to implement Nirsevimab immunization.
Results
From 2022 to 2025, the incidence of hospitalized bronchiolitis decreased significantly, with a reduction of 84% in the 2024–2025 season compared to previous (2021–22, 2022–23, 2023–24) years ( p < 0.0001). In the 2024–2025 season, a significant difference was observed in the percentage of RSV cases in 2025 compared to previous years and a significant reduction in the circulation of non‐RSV viruses. The average hospital stay and clinical severity remained stable throughout the years. Only one hospitalized patient in the 2024–2025 season had received Nirsevimab, presenting with mild bronchiolitis.
Conclusion
The introduction of Nirsevimab in Sicily led to a significant reduction in bronchiolitis incidence, with a reduction of RSV and non‐RSV cases. Clinical severity and hospital stay duration remained unchanged. The findings support the efficacy of Nirsevimab in preventing severe bronchiolitis requiring hospitalization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pediatric Pulmonology and Cystic Fibrosis Unit, AOU Policlinico "G. Rodolico-San Marco", University of Catania, Catania, Italy.
- Pediatric Unit, Department of Human Pathology in Adult and Developmental Age "Gaetano Barresi", University of Messina, Messina, Italy.
Zitieren
APA
Presti, S., Parisi, G. F., Tosto, M., Nizzari, A., Campo, E., Pecora, G., Papale, M., Manti, S., & Leonardi, S. (2026). Effect of Nirsevimab as a Primary Preventive Strategy on the Incidence, Severity, and Viral Etiology of Bronchiolitis: A Four‐Year Observational Study. Pediatric Pulmonology. https://doi.org/10.1002/ppul.71451
Vancouver
Presti S, Parisi GF, Tosto M, Nizzari A, Campo E, Pecora G, et al. Effect of Nirsevimab as a Primary Preventive Strategy on the Incidence, Severity, and Viral Etiology of Bronchiolitis: A Four‐Year Observational Study. Pediatric Pulmonology. 2026. doi:10.1002/ppul.71451
BibTeX
@article{Presti2026,
author = {Presti, Santiago and Parisi, Giuseppe Fabio and Tosto, Monica and Nizzari, Annachiara and Campo, Ersilia and Pecora, Giulia and Papale, Maria and Manti, Sara and Leonardi, Salvatore},
title = {Effect of Nirsevimab as a Primary Preventive Strategy on the Incidence, Severity, and Viral Etiology of Bronchiolitis: A Four‐Year Observational Study},
journal = {Pediatric Pulmonology},
year = {2026},
doi = {10.1002/ppul.71451}
}
EUVIMED